

DeRisio Richard J.
Form 4
February 27, 2009

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
DeRisio Richard J.

2. Issuer Name and Ticker or Trading Symbol
ABBOTT MEDICAL OPTICS INC
[EYE]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction
(Month/Day/Year)
02/25/2009

____ Director
 Officer (give title below)
____ 10% Owner
____ Other (specify below)
Corporate Vice President

C/O ABBOTT MEDICAL OPTICS INC., 1700 E. ST. ANDREW PLACE

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
____ Form filed by More than One Reporting Person

SANTA ANA, CA 92705

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
| | | | Code | V | Amount (A) or (D) Price | | |
| Common Stock | 02/25/2009 | | A | | 4,500 (1) \$ 0 | D | |
| Common Stock | 02/25/2009 | | F | | 1,609 (2) \$ 22.01 | D | |
| Common Stock | 02/26/2009 | | D | | 2,891 (1) \$ 22 0 | D | |
| Common Stock | 02/25/2009 | | A | | 3,000 (1) \$ 0 | D | |
| | 02/25/2009 | | F | | 1,927 | D | |

Edgar Filing: DeRisio Richard J. - Form 4

| | | | | | | | | |
|--------------|------------|---|--|--------------|---|----------|-------|---|
| Common Stock | | | | 1,073 (2) | | \$ | 22.01 | |
| Common Stock | 02/26/2009 | D | | 1,927 (1) | D | \$ 22 | 0 | D |
| Common Stock | 02/25/2009 | A | | 2,500 (1) | A | \$ 0 | 2,500 | D |
| Common Stock | 02/25/2009 | F | | 894 (2) | D | \$ 22.01 | 1,606 | D |
| Common Stock | 02/26/2009 | D | | 1,606 (1) | D | \$ 22 | 0 | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|
| | | | | Code | V (A) (D) | Date Exercisable Expiration Date | Title Amount or Number of Shares |
| Employee Stock Option (Right to Buy) | \$ 30.15 | 02/26/2009 | | D ⁽³⁾ | 21,000 | 02/25/2009 08/27/2017 | Common Stock 21,000 |
| Employee Stock Option (Right to Buy) | \$ 22.94 | 02/26/2009 | | D ⁽⁴⁾ | 10,860 | 02/25/2009 05/29/2018 | Common Stock 10,860 |

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

DeRisio Richard J.
C/O ABBOTT MEDICAL OPTICS INC.
1700 E. ST. ANDREW PLACE
SANTA ANA, CA 92705

Corporate Vice President

Signatures

Richard J. DeRisio, By: Aimee S. Weisner, Attorney
in Fact

02/27/2009

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The exempt restricted stock units (previously reported on Table II) vested in full and were settled for shares of Issuer Common Stock in accordance with the terms of the applicable equity plan. At the effective time of the merger (defined in the Agreement and Plan of Merger

(1) dated January 11, 2009, by and among Abbott Laboratories, Rainforest Acquisition Inc. and the Issuer ("Merger Agreement"), such shares were cancelled pursuant to the Merger Agreement in exchange for the right to receive cash payment of \$22.00 per share in cash (without interest and subject to any required withholding taxes).

(2) Shares withheld in satisfaction of tax obligations attributable to the lapse of restrictions on stock award or in satisfaction of tax withholding attributable to vesting and settlement of restricted stock units.

This previously reported exempt stock option, which was to have vested ratably over the first four years from the date of grant, will be exchanged for a fully vested stock option issued by Abbott Laboratories to purchase 8,616 shares of Abbott Laboratories common stock at an exercise price of \$73.49 per share, determined pursuant to a formula set forth in the Merger Agreement.

(4) This previously reported exempt stock option, which was to have vested ratably over the first four years from the date of grant, will be exchanged for a fully vested stock option issued by Abbott Laboratories to purchase 4,455 shares of Abbott Laboratories common stock at an exercise price of \$55.92 per share, determined pursuant to a formula set forth in the Merger Agreement.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.